Affibody

Affibody: Proprietary Affibody® molecules and Albumod® platforms. Lead candidate ABY-035 is an IL-17 with multiple Ph 2 programs (PSO OLE PsA, axSpA, uveitis). Positive Ph2 52wk data in psoriasis with 2-yr OLE data expected in 2H21. Ph2 IND for lead indication uveitis filed in Q1 2021 with interim data expected in 2022. AB-251 is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Ongoing relationship with Inmagene in China. Backed by Investor AB. $81M raised to date.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Dermatology, Oncology, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Private
Market Cap
Private
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Scheeles väg 2
Solna, Stockholms Lan 17165
Sweden

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • David Bejker, CEO
  • Fredrik Frejd, Prof, CSO

Upcoming Company Event Participation

Lead Programs

ABY-035

Indication Phase